{"as_of":"2026-08-16T11:51:00Z","caps":{"database_statements":6,"inbound":100,"outbound":100},"context_digest":"sha256:32fcfcef3d51579d5c1c8cc8152a9a2bbafb2b4ed232951c0b641a754dd52440","coverage":[{"denominator":33,"lane":"reference_resolution","note":"Typed states for the displayed outbound observations.","records_observed":33,"source":"paper_references, paper_reference_links","source_observed_at":"2026-08-14T12:16:37.765468Z","state":"measured"},{"denominator":33,"lane":"standing_notices","note":"One-hop event checks from named stored sources.","records_observed":33,"source":"scholarly_work_events, retraction_status_cache","source_observed_at":"2026-08-16T06:30:59.297886+00:00","state":"measured"},{"denominator":0,"lane":"inbound_itemization","note":"Pith citing papers itemized under the disclosed page cap.","records_observed":0,"source":"paper_references, paper_reference_links","source_observed_at":null,"state":"measured"},{"denominator":1,"lane":"external_citation_measurements","note":"A source-named dated measurement, never combined with another source.","records_observed":0,"source":"cited_works","source_observed_at":null,"state":"measured"}],"external_citation_measurements":[],"inbound":[],"links":{"evidence":"/evidence","html":"/paper/1908.07751/citation-record","integrity":"/paper/1908.07751/integrity","json":"/paper/1908.07751/citation-record.json","paper":"/paper/1908.07751"},"outbound":[{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:38.155247Z","title":"The ASA’s statement on p-values: Context, process, and purpose","venue":null,"work_id":"fc64bede-d90c-4293-90e6-2fa2a3788983","year":2016},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":1,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.641529Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:7ba8455fdb1de3809a2268cb1072b23dde317a287f62c7e7174af9eb4175ca80","observation_id":"ebf7d88e-9b0a-4715-be22-31c3c7889b83","resolution":{"observed_at":"2026-08-14T12:16:38.159250Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:38.143848Z","title":"One-sample multiple testing procedure for phase II clinical trials","venue":null,"work_id":"c967e452-46cd-41e8-bfc9-5633db6ade78","year":1982},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":2,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.646476Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:08d5930cc485488d187e9e778167f69cee9163c3babc8eae42b7dd59a17abc1c","observation_id":"94783df2-70a4-4bf9-a6ee-aac7bdcfe889","resolution":{"observed_at":"2026-08-14T12:16:38.147475Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:38.132465Z","title":"Calibrated phase II clinical trials in oncology","venue":null,"work_id":"a67cad65-1e1b-4f56-add4-efbbbebf2832","year":1986},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":3,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.651258Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:f813145c64669bae6764567544f3443e64edebc85a4ae2a3e44e35b57a7b0eca","observation_id":"2ef04326-5450-44d9-97ce-92b91e3b0871","resolution":{"observed_at":"2026-08-14T12:16:38.136236Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:38.122471Z","title":"Optimal two-stage designs for phase II clinical trials","venue":null,"work_id":"c75dc41d-6f10-4861-bb4d-e4eb306e5e73","year":1989},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":4,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.655463Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:4d97b057b2e175620dbb3cf5256556742732f2aa39713b0ab52d380b42abac04","observation_id":"5b019c17-e9b8-4ee9-8bbc-b68633ae2049","resolution":{"observed_at":"2026-08-14T12:16:38.125974Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:38.111635Z","title":"Optimal two-stage screening designs for survival comparisons","venue":null,"work_id":"9a025194-c26e-428f-932d-8ab51283cb43","year":1990},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":5,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.659955Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:12e3f020ad161c43f2be08026ea983b3a964ac5fdfe03347729d12d8cdf8a733","observation_id":"2e4473eb-42d9-432a-811f-c06a7010bc93","resolution":{"observed_at":"2026-08-14T12:16:38.115396Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:38.101081Z","title":"A class of phase II designs with three possible outcomes","venue":null,"work_id":"bd5d1651-e386-4a56-a221-372aee78779b","year":1992},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":6,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.665128Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:9cad3cf3125d1e3af4cd3558ee11351847342158586ccc7fbc1b7cc80cd41a51","observation_id":"2822e411-f08a-45ef-a4f1-c79996fb0c7f","resolution":{"observed_at":"2026-08-14T12:16:38.105193Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:38.089109Z","title":"Selection designs for pilot studies based on survival","venue":null,"work_id":"3b314b66-7050-435f-87a8-33c45b2d0a1f","year":1993},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":7,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.669609Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:eb5e19d08d2d08045c63c303c7cd422cede6caa55948bb7761cc37f698fc8775","observation_id":"ba6bc467-db56-4da4-becc-0cb491eb2c5a","resolution":{"observed_at":"2026-08-14T12:16:38.092734Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:38.077786Z","title":"False positive rates of randomized phase II designs","venue":null,"work_id":"66146707-815f-430b-b6e3-f99cf6430c08","year":null},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":8,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.673438Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:95b1a2beb70adebe770e378865ba8dd27d289f4fbbc1196840edaef7fdf198a8","observation_id":"d692cd6a-6e4b-4826-8b89-0683aa22bba8","resolution":{"observed_at":"2026-08-14T12:16:38.081430Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:38.067650Z","title":"A three-outcome design for phase II clinical trials","venue":null,"work_id":"1e028b3d-242a-4c77-b4ea-6a357306afd5","year":2001},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":9,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.677993Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:a19ba1f6ea158375945d7b56a25e4621364b77f168b2decbbd6cff73d1cfcfc8","observation_id":"9f97fd36-db62-47ec-bd55-0ae9e5fff578","resolution":{"observed_at":"2026-08-14T12:16:38.071601Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:38.055991Z","title":"Clinical trial designs for cytostatic agents: Are new approaches needed? Journal of Clinical Oncology 2001; 19(1): 265–272","venue":null,"work_id":"a183911a-b902-4a9b-bbda-c544ad85d337","year":2001},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":10,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.681699Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:f766c25e0ae3bda4b064ac9a5909a01067f91258faaa8108e7cfdae18e929970","observation_id":"f69bcf1e-c0d5-4145-85e5-7405c5c29a27","resolution":{"observed_at":"2026-08-14T12:16:38.061169Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:38.044311Z","title":"Design issues of randomized phase ii trials and a proposal for phase II screening trials","venue":null,"work_id":"b2d52dff-8f48-4d0d-a31f-faf3fb4f453d","year":2005},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":11,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.685103Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:fc80e1eee2a43d0ab4a9ed71f08b380646adfc8c386eec3b21023913404677e5","observation_id":"c841bed1-08e3-4f73-968d-9af368dc1417","resolution":{"observed_at":"2026-08-14T12:16:38.048383Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:38.033715Z","title":"Clinical trial designs for the early clinical development of therapeutic cancer vaccines","venue":null,"work_id":"f146ff1d-7f35-43f2-a8ef-febd6bc33748","year":2001},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":12,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.688744Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:d277632b7336ed7110efbf2715bd970b47592db632fd3b241ef969b4207fb51f","observation_id":"09b6d6c4-3f63-4a29-8ad9-d0dfafebcc36","resolution":{"observed_at":"2026-08-14T12:16:38.037361Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:38.023134Z","title":"An optimal stratified Simon two-stage design","venue":null,"work_id":"b28cd11f-56df-42a2-bb2a-a4a5aedbb56f","year":2016},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":13,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.692033Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:e7953238d1bfb96456b1608f55c2b5a8f0e713c2b5cf1313c5b38451339a7833","observation_id":"4144b912-39ae-4cc3-9a62-47c2f14dea94","resolution":{"observed_at":"2026-08-14T12:16:38.027373Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:38.012994Z","title":"Proof of concept: a PhRMA position paper with recommendations for best practice","venue":null,"work_id":"7eff9fae-7179-4f00-a29e-e5f2258a0008","year":2010},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":14,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.695494Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:452a85ed01fe30244b851ad84ec0dd748e1d185c8d72696e0e19274db202faec","observation_id":"54418981-0e46-4b1b-b5e7-f746d1f61637","resolution":{"observed_at":"2026-08-14T12:16:38.016939Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:38.001981Z","title":"A consonance criterion for choosing sample size","venue":null,"work_id":"55f595c4-9e4e-4195-9521-e21bf9aa7613","year":1997},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":15,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.700064Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:c6b4bad8f8a424d94055897a17cfccb4b18c7dc5c5b8363a554d7cf2ab85167b","observation_id":"dc24fdae-4342-4512-a53d-2ae1761aa3aa","resolution":{"observed_at":"2026-08-14T12:16:38.006158Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:37.990549Z","title":"The role of the minimum clinically important difference and its impact on designing a trial","venue":null,"work_id":"9cf52208-4703-4d41-9dce-405a971b6a4a","year":2011},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":16,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.704955Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:7738cc86f3d06612245ed315ad6fcd36c213cfac70f296e524c86ccf98cf2f5b","observation_id":"6d488fa0-ec8e-46dc-a3a0-5cd4bbecee8e","resolution":{"observed_at":"2026-08-14T12:16:37.995099Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:37.979193Z","title":"A quantitative approach for making GO/NO-GO decisions in drug develop- ment","venue":null,"work_id":"3977646d-2a04-4748-9492-8cf5375a665d","year":2011},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":17,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.708194Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:6aafeb2a3e050530be74971e94e354f9204b7cdc7105db554c716db579298dfc","observation_id":"974401c4-70aa-456c-9e64-58cfd5b82d80","resolution":{"observed_at":"2026-08-14T12:16:37.983594Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:37.967468Z","title":"A proof of concept phase II non-inferiority criterion","venue":null,"work_id":"1266eec5-982b-453a-a202-5bd97472c4a3","year":2011},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":18,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.711505Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:27c061c30ab01ff1ac5deff755d9bf6d969c42913585472d7dd02bbf3fffa570","observation_id":"89fab669-0384-4b59-b20a-f566492f9f2d","resolution":{"observed_at":"2026-08-14T12:16:37.972439Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:37.955344Z","title":"Bayesian design of proof-of- concept trials","venue":null,"work_id":"46c077f1-71e0-40ad-a69e-0214f3e9c7e7","year":2015},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":19,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.714593Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:7cbadad6cd9f8c5936c1387cc63004ebf826481fe5e36fe10af5d54912f9e340","observation_id":"b98d0029-ffcb-4e06-976c-0c865dca8faa","resolution":{"observed_at":"2026-08-14T12:16:37.959657Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:37.942810Z","title":"Decision-making in early clinical drug development","venue":null,"work_id":"f8e41de8-5eb2-45c2-92ad-e0e398cb413f","year":2016},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":20,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.717557Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:25b650ef95c5c05887ffc2cf01f88daac69b7f1425a39aab8455ac51783d1812","observation_id":"944eb495-03cb-4972-bf6c-47714d998d82","resolution":{"observed_at":"2026-08-14T12:16:37.947281Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:37.930753Z","title":"Statistical issues in drug development","venue":null,"work_id":"5693c958-b1dd-4fc1-9cdf-77614deadedc","year":1997},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":21,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.721174Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:526f6184c3d538344941b18fa7ff4ce2f960493c1329b719895e00fc4363cb4d","observation_id":"117008b9-b18b-493d-83c3-33a9b5edde5f","resolution":{"observed_at":"2026-08-14T12:16:37.934565Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:37.920449Z","title":"Reconciling Bayesian and frequentist evidence in the one-sided testing problem (C/R: P123-135)","venue":null,"work_id":"d6ecb123-5dc5-487e-9048-aa43890af955","year":1987},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":22,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.725492Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:c67f93d1a99bc44c683010be848b6c4b970a2093b8edc894899796dab6fedc95","observation_id":"a69493e0-d736-4038-824d-0a68cebcd1e0","resolution":{"observed_at":"2026-08-14T12:16:37.924325Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:37.908311Z","title":"Testing a point null hypothesis: The irreconcilability of P values and evidence (C/R: P123-133, 135-139, 1201-1201)","venue":null,"work_id":"37520976-af33-4d0f-9c9e-e68c9a037ac8","year":1987},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":23,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.728898Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:34beb70719cbe387c8f1f3d4e41b21ae584a894196005922b8c270324abfff2b","observation_id":"d9e39fca-644b-43e5-a0a8-8093bd2abec1","resolution":{"observed_at":"2026-08-14T12:16:37.912489Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:37.897502Z","title":"R: A Language and Environment for Statistical Computing","venue":null,"work_id":"f3e3a67d-7948-4370-82e4-81526f1dc970","year":2015},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":24,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.732384Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:0b0fc9100f89413ff15f85ac790499f74da0cbd3a1294afd8c0597ae31915d5a","observation_id":"c24cf587-1233-44d7-91ae-b1f47e511a8c","resolution":{"observed_at":"2026-08-14T12:16:37.901190Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:37.885229Z","title":"A practical guide to bayesian group sequential designs","venue":null,"work_id":"d023ec87-91ae-43df-93c4-c294fe501d76","year":2014},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":25,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.735797Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:49b0ed4eb697b56defbb472d71c17d6a1570383e11001551cb16a6ea2e66f76f","observation_id":"878f4b82-343f-45a0-836e-5c4165a3e713","resolution":{"observed_at":"2026-08-14T12:16:37.889876Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:37.873651Z","title":null,"venue":null,"work_id":"f54732ba-3c6a-42f8-896d-1a5bea27f3f6","year":null},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":26,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.739453Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:fd0d91722fc1dc3f2cbdba1e1bb6c80645fc699e031fedcf6aa7b5eb466e2d57","observation_id":"1cb8d319-9adb-4918-a3f7-4392dc36e2b8","resolution":{"observed_at":"2026-08-14T12:16:37.877297Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:37.863362Z","title":null,"venue":null,"work_id":"023d8b7c-7c35-4623-a875-d2dfdb144522","year":null},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":27,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.743290Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:f7a131642a59276db9a21f51c67865f4e1c52c1de889f904bd594edba2a62940","observation_id":"862a0b44-0562-4c10-9bbb-c3bb77ba8c10","resolution":{"observed_at":"2026-08-14T12:16:37.866896Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:37.849715Z","title":null,"venue":null,"work_id":"8df8eb5a-0c1e-4b2b-bff3-5930c4fed6f8","year":null},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":28,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.746901Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:1996f6d876feced623032ff264933358458f7acf5d1b2cd55d3b3e4306e2a943","observation_id":"924fd43c-f3bb-4387-abd4-9bfb92f65464","resolution":{"observed_at":"2026-08-14T12:16:37.854544Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:37.837516Z","title":null,"venue":null,"work_id":"a16888c7-a2b0-49d3-a284-2475a2cba163","year":null},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":29,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.750390Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:2ac2e90196b5f577d3f36bd0330affa06520bfdf0ed98523fd8b473fa07f1b9a","observation_id":"09be5e04-257d-4667-a303-bf03c5f11ecd","resolution":{"observed_at":"2026-08-14T12:16:37.841187Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:37.823616Z","title":"Example 2: operating characteristics for dual-criterion and three-outcome designs; probabilities for GO, NO-GO and inconclusive decisions given by the number of responders (r)","venue":null,"work_id":"f8b8ae72-e320-43e6-8c60-f156f6e4f14e","year":null},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":30,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.755038Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:fe6a9722c26dcf6a7c6cb79c0fb6ab5be1811291a5080308f24a46fa710bd59a","observation_id":"4451bf1a-7eb4-48aa-956b-b6e72616d58b","resolution":{"observed_at":"2026-08-14T12:16:37.829014Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:37.811008Z","title":null,"venue":null,"work_id":"eb17b20f-0af9-4792-b92a-953c3ad0c999","year":null},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":31,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.758818Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:16fa0b948c9ea7aa1532581aced6a0ac6a7676bc9f26070d21803b0eb4540df8","observation_id":"0253ebe3-d98b-4a8d-a6fd-19ee923e12a0","resolution":{"observed_at":"2026-08-14T12:16:37.815325Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:37.800820Z","title":null,"venue":null,"work_id":"695d9bc8-e6ac-4081-b10a-a309831da7c1","year":null},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":32,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.762278Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:f7f5e3ff372a4ceb2272df0f2a286e26c0203f3899ac0a1cb21ce80201bced42","observation_id":"14323ec5-ceb2-445b-9658-0ad23392c55c","resolution":{"observed_at":"2026-08-14T12:16:37.804053Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:16:37.788523Z","title":null,"venue":null,"work_id":"afb4df2e-a8ae-4887-b86d-6aae8ef4c3de","year":null},"citing_paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance","version":1},"reference_index":33,"source":"pdf_text","source_observed_at":"2026-08-14T12:16:37.765468Z"},"links":{"citing_paper":"/paper/1908.07751"},"observation_digest":"sha256:24f23ac819a20c798b1cb2088199018d199f8fd37c2621b296ba39a8b43ec4bb","observation_id":"f5a9331b-b173-4e30-9ece-82b9258a5548","resolution":{"observed_at":"2026-08-14T12:16:37.792759Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}}],"paper":{"arxiv_id":"1908.07751","last_updated":"2019-08-21T08:44:52Z","latest_version":1,"primary_category":"stat.AP","snapshot_observed_at":"2026-08-16T04:35:50.598338Z","submitted_at":"2019-08-21T08:44:52Z","title":"Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance"},"reference_resolution":{"displayed":33,"state_counts":{"malformed_identifier":0,"metadata_mismatch":0,"parse_uncertain":0,"unresolved":7,"verified_exact":0,"verified_fuzzy":26},"total_outbound_references":33},"refusal":"A citation records a reference. It does not transfer a finding from one paper to another.","schema":"pith.paper-citation-record.v1","standing_sources":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"thesis":"As of 16 August 2026, this Paper Citation Record lists 33 of 33 outbound references and 0 inbound Pith citation observations for arXiv:1908.07751."}